FIELD: medicine.
SUBSTANCE: invention refers to medicine, and concerns a method of treating a patient having a non-small cell lung cancer with ALK translocation involving administering a therapeutically effective amount of ceritinib in a combination with nivolumab to said patient.
EFFECT: invention provides immune response modulation.
1 cl, 1 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN TREATING CANCER | 2016 |
|
RU2834309C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| ANTIBODIES TO PD-1(CD279) | 2017 |
|
RU2752562C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| COMBINATION OF PD-1 ANTAGONIST, VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER | 2020 |
|
RU2838452C1 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| ANTIBODY-BASED PROTEINS WITH CYTOKINE GRAFTS AND METHODS OF THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2815389C2 |
